1 |
Tang L, Yu X, Zou L, Li S, Cheng Y, Wu Y, Xing L, Fang H. Qinggan Huoxue Recipe Protects against Experimental Alcoholic Liver Fibrosis through CXCL16 Inhibition. Evid Based Complement Alternat Med 2023;2023:5642713. [PMID: 36636609 DOI: 10.1155/2023/5642713] [Reference Citation Analysis]
|
2 |
Bukke VN, Moola A, Serviddio G, Vendemiale G, Bellanti F. Nuclear factor erythroid 2-related factor 2-mediated signaling and metabolic associated fatty liver disease. World J Gastroenterol 2022; 28(48): 6909-6921 [DOI: 10.3748/wjg.v28.i48.6909] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
3 |
Li H, Zhao C, Muhetaer G, Guo L, Yao K, Zhang G, Ji Y, Xing S, Zhou J, Huang X. Integrated RNA-sequencing and network pharmacology approach reveals the protection of Yiqi Huoxue formula against idiopathic pulmonary fibrosis by interfering with core transcription factors. Phytomedicine 2022;104:154301. [PMID: 35792448 DOI: 10.1016/j.phymed.2022.154301] [Reference Citation Analysis]
|
4 |
Artlett CM. The Mechanism and Regulation of the NLRP3 Inflammasome during Fibrosis. Biomolecules 2022;12:634. [DOI: 10.3390/biom12050634] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
5 |
Liao HJ, Tzen JTC. The Potential Role of Phenolic Acids from Salvia miltiorrhiza and Cynara scolymus and Their Derivatives as JAK Inhibitors: An In Silico Study. Int J Mol Sci 2022;23:4033. [PMID: 35409393 DOI: 10.3390/ijms23074033] [Reference Citation Analysis]
|